Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
Nurix Therapeutics (Nasdaq: NRIX) announced that CEO Arthur T. Sands will join a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 2:15 PM ET. The session will be broadcast live and can be accessed via Nurix's website, with an archived version available for 30 days post-event. Nurix is focused on discovering and developing drugs that modulate protein levels to treat cancer and other diseases through its innovative platform targeting E3 ligases.
- Participation in a recognized healthcare conference, increasing visibility among investors.
- The focus on innovative drug discovery efforts targeting E3 ligases shows potential for future growth.
- None.
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 2:15 PM ET.
The event will be webcast live and may be accessed via the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com.
Contacts:
| Investors: | Media: |
| Elizabeth Wolffe, Ph.D. | Brett Whelan |
| Wheelhouse Life Science Advisors | LifeSci Communications |
| lwolffe@wheelhouselsa.com | bwhelan@lifescicomms.com |
FAQ
What is the date and time of Nurix Therapeutics' fireside chat at the Needham Conference?
Where can I watch the Nurix Therapeutics conference presentation?
What is the focus of Nurix Therapeutics as a biopharmaceutical company?
What innovative approach does Nurix Therapeutics use in drug discovery?
